The Indian Pharmaceutical Market to 2011: Competitive Dynamics and Major Players.

LYON, France -- Reportlinker.com announces that a new market research report related to the Indian pharmaceutical industry is now available to its catalogue.

The Indian Pharmaceutical Market to 2011: Competitive dynamics and major players

http://www.reportlinker.com/p054677/Indian- Pharmaceutical-Market.html

(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics' manufacturing and relatively immature capabilities in R&D. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities. The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams, enabling Indian pharma companies to experience high market growth.

The report provides a detailed analysis of the leading players and discusses how they are planning to sustain growth over the next five years. For each company, this report analyzes current and future therapeutic focus, sales growth, key pipeline products and future growth prospects.

This report will help you to identify the critical success factors that have driven company growth, evaluate diversification opportunities and assess the future potential of each company's R&D portfolio over the next five years.

Key findings of the report...

* In 2005, the Indian pharmaceutical industry was valued at $4,660m, representing an increase of 8.3% over year previous sales of $4,304m. A surge in growth is expected to take place between 2006 and 2008, attributable to the opportunities presented by contract research and manufacturing sourcing (CRAMS).

* MNCs have a modest representation among the top 20 companies in the Indian pharmaceutical industry. As the market leader, GSK captured a 6.3% share, illustrating the highly fragmented nature of the market.

* The re-introduction of the patent regime in 2005 has forced many smaller Indian companies to exit the industry, while others have been forced to re-evaluate existing corporate strategies.

* The Indian market has been associated with commodity generics, although a shift in priorities has occurred with many companies increasing their investments in research capabilities and thus establishing themselves as development partners of choice with international companies.

Key questions answered in this report

* What are the challenges faced by pharmaceutical companies in the Indian market?

* How has the re-introduction of patent regime affected Indian pharmaceutical companies?

* What are the market shares for the ten leading Indian companies 2005?

* Which of the top ten companies are out performing and under performing in the current market situation and why?

* What are the major strengths, weaknesses, opportunities and threats for the market leaders?

* Which of the ten companies features the most promising R&D pipeline and how will this impact future growth?

Top five reasons to order your copy today

* Gain insights from the best practices of the top 10 Indian pharma companies, by reviewing detailed profiles of current and future drug portfolios, growth strategies and organizational structure.

* Assess the pipeline strength of the top 10 Indian Pharma companies and identify future opportunities for growth.

* Evaluate how market share of leading companies, such as Ranbaxy, Cipla, Nicholas Piramal, Sun Pharma and Zydus Cadila will change over the next 5 years.

* Benchmark forecast performance of the leading players by using analysis of key products in major indications.

* Identify which therapy areas offer the greatest opportunity by evaluating the therapeutic focus of the competition.

Table of content

Executive Summary

The Indian Pharmaceutical Market

Company Analysis

Future Outlook for the Indian pharmaceutical industry

Chapter 1 The Pharmaceutical Market Environment in India

Summary

Introduction

Pharmaceutical market environment in India

Pharmaceutical spending in the Indian market

Performance of Therapeutic Areas

Performance of leading companies in the Indian market

Leading products in the Indian pharmaceutical market

Factors shaping the Indian pharmaceutical market

Chapter 2 Company analysis

Summary

Introduction

Indian Market analysis by company

Cipla

Company Overview

Geographic Presence

Product Portfolio Analysis

Sales focus by therapy area

Marketed Portfolio

R&D Pipeline

Strategic Positioning

SWOT analysis

Corporate Strategy

Ranbaxy

Company Overview

Geographic Presence

Product Portfolio Analysis

Sales focus by therapy area

Marketed Portfolio

R&D Pipeline

Strategic Positioning

SWOT analysis

Corporate Strategy

Nicholas Piramal

Company Overview

Geographic Presence

Product Portfolio Analysis

Sales focus by therapy area

Marketed Portfolio

R&D Pipeline

Strategic Positioning

SWOT analysis

Corporate Strategy

Sun Pharmaceuticals

Company Overview

Geographic Presence

Product Portfolio Analysis

Sales focus by therapy area

Marketed Portfolio

R&D Pipeline

Strategic Positioning

SWOT analysis

Corporate Strategy

Zydus Cadila

Company Overview

Geographic Presence

Product Portfolio Analysis

Sales focus by therapy area

Marketed Portfolio

R&D Pipeline

Strategic Positioning

SWOT analysis

Corporate Strategy

Dr. Reddy's

Overview

Geographic analysis

Product portfolio analysis

Sales focus by therapy area

Marketed portfolio

R&D pipeline

Strategic positioning

SWOT analysis

Corporate strategy

Alkem

Company Overview

Geographic Presence

Product Portfolio Analysis

Sales focus by therapy area

Marketed Portfolio

R&D pipeline

Strategic Positioning

SWOT analysis

Corporate strategy

Lupin

Company overview

Geographic analysis

Product portfolio

Sales focus by therapy area

Marketed portfolio analysis

R&D pipeline

Strategic positioning

SWOT analysis

Corporate strategy

Aristo

Company overview

Geographic analysis

Product portfolio

Sales focus by therapy area

Marketed portfolio analysis

R&D pipeline

Strategic Positioning

SWOT analysis

Corporate strategy

Torrent

Company overview

Geographic analysis

Product portfolio

Sales focus by therapy area

Marketed portfolio analysis

R&D pipeline

Strategic Positioning

SWOT analysis

Corporate strategy

Company forecast sales for the period 2005-11

Chapter 3 Future Outlook and Competitive Pressures

Summary

Introduction

Competitive pressures being faced by the Indian companies

Re-introduction of product patent regime in 2005

Market saturation in the Indian market across major therapy areas

Increasing competition from other low cost manufacturing markets such as China

Stringent pricing controls on numerous essential medicines

Future Indian pharmaceutical growth models

Value versus volume driven market

Contract Research and Manufacturing Sourcing (CRAMS)

Contract Manufacturing

Contract Research and low cost clinical trials

Mergers and acquisitions

Chapter 4 Appendix

IMS data

Index

More market research reports? Go to http://www.reportlinker.com

http://www.reportlinker.com/Rss/en016069/pharmaceutical- acquisition-free-market-research-reports.xml

http://www.reportlinker.com/Rss/en016068/pharmaceutical- firm-free-market-research-reports.xml

http://www.reportlinker.com/Rss/en012978/pharmaceutical- industry-free-market-research-reports.xml

http://www.reportlinker.com/Rss/en016066/pharmaceutical- merger-free-market-research-reports.xml

http://www.reportlinker.com/Rss/en013013/pharmacoeconomic- analysis-free-market-research-reports.xml

(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)